Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Status:
Completed
Trial end date:
2012-01-03
Target enrollment:
Participant gender:
Summary
Idiopathic osteoporosis (IOP) is an uncommon disorder in which otherwise healthy young
individuals sustain one or more low-trauma fractures. Teriparatide [PTH(1-34)], which is FDA
approved for treatment of osteoporosis in men and postmenopausal women, works by stimulating
bone formation. The investigators hypothesize that teriparatide will significantly increase
bone density (BMD) and improve bone structure in premenopausal women with IOP.